Celldex reports Q3 net loss of $20.5M, cash $423M, CDX-0159 95% complete response.

Celldex Therapeutics, Inc.

2022-Q3 EPS reported -$1.21 revenue$4,317,000

Net loss $20.5M ($0.45/share) in Q3 2021; revenue $0.2M, vs net loss $14.2M ($0.36/share) in Q3 2020.
Cash, cash equivalents & marketable securities $423.1M at Sept 30, 2021, up from $164M at June 30; cash runway through 2025.
CDX-0159 Phase 1b in inducible urticaria: 95% complete response (18/19) after single dose; median response duration 77+ days (cold urticaria) and 57+ days (symptomatic dermographism).
Completed $287.5M gross public offering in July 2021; net proceeds $269.9M.
CDX-1140 combo with pembrolizumab shows confirmed partial response in head and neck cancer; ovarian expansion enrolling for CDX-527.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.